We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF) (SALIF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01424137
Recruitment Status : Completed
First Posted : August 26, 2011
Last Update Posted : February 3, 2012
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

Brief Summary:
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with chronic obstructive pulmonary disease (COPD).

Condition or disease Intervention/treatment Phase
Asthma Chronic Obstructive Pulmonary Disease Device: Easyhaler type A Device: Easyhaler type B Device: Diskus inhaler Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 227 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Inspiratory Flow Parameters With Placebo Dry Powder Inhalers, Easyhaler and Diskus; an Open, Randomised, Multicentre Study in Patients With Asthma or COPD
Study Start Date : September 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Easyhaler type A Device: Easyhaler type A
Easyhaler type A inhaler, 3 consecutive inhalations
Other Name: SF EH (D94-2SF)

Easyhaler type B Device: Easyhaler type B
Easyhaler type B inhaler, 3 consecutive inhalations
Other Name: SF EH (D94-2SF-B)

Diskus inhaler Device: Diskus inhaler
Diskus inhaler, 3 consecutive inhalations
Other Name: Inhaler for Seretide Diskus

Primary Outcome Measures :
  1. Peak inspiratory flow rate through the placebo Easyhaler and Diskus inhalers [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. The inspiratory volume through the placebo Easyhaler and Diskus inhalers will be measured at the same time with the peak inspiratory flow rate [ Time Frame: 1 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent (IC) obtained
  • Documented diagnosis of asthma and/or COPD
  • Age: 4 years and above

Exclusion Criteria:

  • Any severe chronic respiratory disease other than asthma or COPD
  • Acute respiratory infection
  • Any medical condition that in the opinion of the investigator would endanger the subject if he/she participates in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01424137

Layout table for location information
Lasnamäe Medicum
Tallinn, Estonia, 13619
Children's Clinic of Tartu, Allergy Centre
Tartu, Estonia, 51014
Tartu University Hospital, Lung Clinic
Tartu, Estonia, 51014
Jorvi Hospital HUS
Espoo, Finland, 02740
Turku University Hospital
Turku, Finland, 20520
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Layout table for investigator information
Study Director: Kati Kaijasilta Orion Corporation, Orion Pharma
Layout table for additonal information
Responsible Party: Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier: NCT01424137    
Other Study ID Numbers: 3106002
First Posted: August 26, 2011    Key Record Dates
Last Update Posted: February 3, 2012
Last Verified: February 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Fluticasone-Salmeterol Drug Combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists